Intervention Protocol

You have free access to this content

Methylphenidate for core and ADHD-like symptoms in children aged 6 to 18 years with autism spectrum disorders (ASDs)

  1. Toni Redman1,
  2. Elly Scheermeyer2,
  3. Makoto Ogawa2,
  4. Eddie C Sparks2,
  5. Jeremy C Taylor2,
  6. Vi T Tran2,
  7. Nancy Sturman3,
  8. Mieke L van Driel2,4,5,*

Editorial Group: Cochrane Developmental, Psychosocial and Learning Problems Group

Published Online: 13 AUG 2014

DOI: 10.1002/14651858.CD011144

How to Cite

Redman T, Scheermeyer E, Ogawa M, Sparks EC, Taylor JC, Tran VT, Sturman N, van Driel ML. Methylphenidate for core and ADHD-like symptoms in children aged 6 to 18 years with autism spectrum disorders (ASDs) (Protocol). Cochrane Database of Systematic Reviews 2014, Issue 8. Art. No.: CD011144. DOI: 10.1002/14651858.CD011144.

Author Information

  1. 1

    Child Development and Behaviour Service, Community Child Health, Gold Coast, Queensland, Australia

  2. 2

    The University of Queensland, School of Medicine, Brisbane, Queensland, Australia

  3. 3

    The University of Queensland, Discipline of General Practice, School of Medicine, Brisbane, Queensland, Australia

  4. 4

    Bond University, Centre for Research in Evidence-Based Practice (CREBP), Gold Coast, Queensland, Australia

  5. 5

    Ghent University, Department of General Practice and Primary Health Care, Ghent, Belgium

*Mieke L van Driel,

Publication History

  1. Publication Status: New
  2. Published Online: 13 AUG 2014



Additional references

  • Australian Advisory Board on Autism Spectrum Disorders. The prevalence of autism in Australia: can it be established from existing data? Overview and report. (accessed 12 November 2013).
AAP 2001
  • American Academy of Pediatrics, Committee on Children with Disabilities. The pediatrician's role in the diagnosis and management of autistic spectrum disorder in children. Pediatrics 2001;107(5):1221-6.
Abidin 1983
  • Abidin RR. Parenting Stress Index: Manual, Administration Booklet and Research Update. Charlottesville: Paediatric Psychology Press, 1983.
Achenbach 1991
  • Achenbach TM. Manual for the Child Behaviour Checklist (CBCL), the Teachers Report Form (TRF) and the Youth Self Report (YSR). Burlington, VT: Department of Psychiatry, University of Vermont, 1991.
APA 1987
  • American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd Edition. Washington, DC: American Psychiatric Association, 1987.
APA 1994
  • American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington, DC: American Psychiatric Association, 1994.
APA 2000
  • American Psychiatric Association. Diagnostic and Stastical Manual of Mental Disorders. 5th Edition. Washington, DC: American Psychiatric Association, 2000.
Benderix 2007
  • Benderix Y, Sivberg B. Siblings' experiences of having a brother or sister with autism and mental retardation: a case study of 14 siblings from five families. Journal of Pediatric Nursing 2007;22(5):410–8.
Bertoglio 2009
Burack 1997
  • Burack JA, Ennis JT, Johannes EA. Attention and autism: behavioral and electrophysiological evidence. In: Cohen DJ, Volkmar FR editor(s). Handbook of Autism and Pervasive Developmental Disorder. 2nd Edition. New York: John Wiley & Sons, 1997:226-47.
Castells 2011
Cortese 2012
  • Cortese S, Castelnau P, Morcillo C, Roux S, Bonnet-Brilhault F. Psychostimulants for ADHD-like symptoms in individuals with autism spectrum disorders. Expert Review of Neurotherapeutics 2012;12(4):461-73.
Croen 2006
  • Croen LA, Najjar DV, Ray GT, Lotspeich L, Bernal P. A comparison of health care utilization and costs of children with and without autism spectrum disorders in a large group-model health plan. Pediatrics 2006;118(4):e1203–11.
Egger 2001
  • Egger M, Davey Smith G, Altman DG (editors). Systematic Reviews in Health Care: Meta-Analysis in Context. 2nd Edition. London, UK: BMJ Publishing Group, 2001.
Filipek 1999
  • Filipek PA, Accardo PJ, Baranek GJ, Cook Jr EH, Dawson G, Gordon B, et al. The screening and diagnosis of autistic spectrum disorders. Journal of Autism and Developmental Disorders 1999;29(6):439-84.
Filipek 2000
  • Filipek PA, Accardo PJ, Ashwal S, Baranek GT, Cook Jr EH, Dawson G, et al. Practice parameter: screening and diagnosis of autism: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Child Neurology Society. Neurology 2000;55(4):468-79.
  • Brozek J, Oxman A, Schünemann H. GRADEprofiler. 3.2 for Windows 2008. [:]
Handen 2000
  • Handen BL,  Johnson CR, Lubetsky M. Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. Journal of Autism and Developmental Disorders 2000;30(3):245-55.
Higgins 2005
  • Higgins DJ, Bailey SR, Pearce JC. Factors associated with functioning style and coping strategies of families with a child with an autism spectrum disorder. Autism 2005;9(2):125–37.
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from
Hyman 2013
  • Hyman SL. New DSM-5 includes changes to autism criteria. AAP News: (accessed 24 May 2014).
Jesner 2007
Kanner 1943
  • Kanner L. Autistic disturbances of affective contact. Nervous Child 1943;2:217-50.
Liberati 2009
Lord 2000
  • Lord C, Risi S, Lambrecht L, Cook Jr EH, Leventhal BL, DiLavore PC, et al. The autism diagnostic observation schedule-generic: a standard measure of social and communication deficits associated with the spectrum of autism. Journal of Autism Developmental Disorders 2000;30(3):205-23.
Mayo Clinic 2014
  • Mayo Clinic. Methylphenidate (oral route). (accessed 5 April 2014).
Medsafe 2010
  • New Zealand Medicines and Medical Devices Safety Authority. Methylphenidate - updated guidance when treating children. (accessed 24 May 2014).
NICE 2013
  • National Institute for Health and Care Excellence. Autism - the management and support of children and young people on the autism spectrum. (accessed 1 April 2014).
NICHD 2014
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development. Autism Spectrum Disorder (ASD): overview. (accessed 5 April 2014).
Nicolson 2000
  • Nicolson R, Castellanos FX. Commentary: considerations on the pharmacotherapy of attention deficits and hyperactivity in children with autism and other pervasive developmental disorders. Journal of Autism and Developmental Disorders 2000;30(5):461-2.
Parr 2008
  • Parr J. Autism. (accessed 5 April 2014).
RevMan 2012
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
Rossi 2010
  • Rossi S, Hurley E, Sutcliffe A, Abott F, Cardinal T, Curtis J, et al. Australian Medicines Handbook. 11th Edition. Adelaide: Australian Medicines Handbook Pty Ltd, 2010.
RUPP Autism Network 2005
  • Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Archives of General Psychiatry 2005;62(11):1266-74.
Santosh 2006
Scahill 2005
Scahill 2006
  • Scahill L, McDougle CJ, Williams SK, Dimitropoulos A, Aman MG, McCracken JT, et al. Children's Yale-Brown Obsessive Compulsive Scale modified for pervasive developmental disorders. Journal of the American Academy of Child and Adolescent Psychiatry 2006;45(9):1114-23.
Siegel 2012
SIGN 2007
  • Scottish Intercollegiate Guidelines Network. Assessment, diagnosis and clinical interventions for children and young people with autism spectrum disorders: a national clinical guideline. (accessed 11 April 2014).
Szymansk 2001
  • Szymansk ML, Zolotor A. Attention-deficit/hyperactivity disorder: management. American Family Physician 2001;64(8):1355-63.
TGL 2012
  • Therapeutic Guidelines Limited. Management Guidelines: Developmental Disability. Version 3. Melbourne: Therapeutic Guidelines Limited, 2012.
Volkow 2001
  • Volkow ND, Wang G, Fowler JS, Logan J, Gerasimov M, Maynard L, et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. Journal of Neuroscience 2001;21(2):RC121.
Wagner 2007
  • Wagner A, Lecavalier L, Arnold LE, Aman MG, Scahill L, Stigler KA, et al. Developmental Disabilities Modification of Children’s Global Assessment Scale (DD-CGAS). Biological Psychiatry 2007;61(4):504-11.
WHO 2007
  • World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. 10th Edition. Geneva: World Health Organization, 2007.
Williams 2006
Williams 2010
Wing 1997